While there has been significant progress in advancing novel immune therapies to the bedside, much more needs to be done to fully tap into the potential of the immune system. It has become increasingly clear that besides practical and operational challenges, the heterogeneity of cancer and the limited efficacy profile of current immunotherapy platforms are the two main hurdles. Nevertheless, the promising clinical data of several approaches point to a roadmap that carries the promise to significantly advance cancer immunotherapy. A new annual series sponsored by Arrowhead Publishers and Conferences aims at bringing together scientific and business leadership from academia and industry, to identify, share and discuss most current priorities in research and translation of novel immune interventions. This Editorial provides highlights of the first event held earlier this year and outlines the focus of the second meeting to be held in 2013 that will be dedicated to stem cells and immunotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551774 | PMC |
| http://dx.doi.org/10.1186/1479-5876-10-218 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Retrospective analysis of disease characteristics and treatment patterns among patients with esophageal cancer across 14 surgically represented centers.
Cancer Biol Med
January 2025
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Objective: Esophageal cancer (EC) ranks eighth among cancers in cancer-related deaths globally, and ~44% of new cases occur in China. We sought to describe the clinical characteristics and treatment landscape of EC in China before the approval of immunotherapy in 2020.
Methods: CHANNEL was a large, retrospective study using patient-level data from 14 hospitals/cancer centers across China, including adults initiating therapy for newly diagnosed EC (January to December 2018).
Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke.
J Vis Exp
January 2025
Department of Physiology, West China School of Basic Medical Sciences and Forensic Medicine, Sichuan University;
Stroke is a leading cause of death and disability worldwide. Most cases of stroke are ischemic and result from the occlusion of the middle cerebral artery (MCA). Current pharmacological approaches for the treatment of ischemic stroke are limited; therefore, novel therapies providing effective neuroprotection against ischemic injury following stroke are urgently needed.
View Article and Find Full Text PDFNitrogen-modified reduced graphene oxide for serum enrichment of -glycans and MALDI-TOF MS-based identification of HCC biomarkers.
Analyst
January 2025
Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, PR China.
Protein -glycosylation, as one of the most crucial post-translational modifications, plays a significant role in various biological processes. The structural alterations of -glycans are closely associated with the onset and progression of numerous diseases. Therefore, the precise and specific identification of disease-related -glycans in complex biological samples is invaluable for understanding their involvement in physiological and pathological processes, as well as for discovering clinical diagnostic biomarkers.
View Article and Find Full Text PDFBackground: Several studies evaluated peripheral and cerebrospinal fluid (CSF) mtDNA as a putative biomarker in neurodegenerative diseases, often yielding inconsistent findings. We systematically reviewed the current evidence assessing blood and CSF mtDNA levels and variant burden in Parkinson's disease (PD), Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). Multiple sclerosis (MS) was also included as a paradigm of chronic neuroinflammation-driven neurodegeneration.
View Article and Find Full Text PDFPredicting Robotic Hysterectomy Incision Time: Optimizing Surgical Scheduling with Machine Learning.
JSLS
January 2025
Department of Obstetrics and Gynecology, NYU Langone Health Grossman School of Medicine, New York, New York, USA. (Drs. V. Shah, Munoz, and Huang).
Background And Objectives: Operating rooms (ORs) are critical for hospital revenue and cost management, with utilization efficiency directly affecting financial outcomes. Traditional surgical scheduling often results in suboptimal OR use. We aim to build a machine learning (ML) model to predict incision times for robotic-assisted hysterectomies, enhancing scheduling accuracy and hospital finances.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!